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Advances in Emerging Therapies 2007
Terence J. Quinn, MRCP; Kennedy R. Lees, MD, FRCP
Cynics may consider that review of emergent stroketherapies in 2007 is likely to make for quick reading—it
is certainly true that many high profile trials reported unex-
pected neutral outcomes. However, although these disap-
pointments made for headline medical news, there were still
a number of encouraging results of novel acute therapies.
The first “casualty” of the year was neuroprotection. The
free radical trapping agent NXY-059 had been consistently
shown to reduce infarct size and improve functional out-
comes in published reports of animal models. The first phase
III study in humans (SAINT) was positive, reporting a
statistically significant improvement in global disability (Fig-
ure).1 Unfortunately, the follow up SAINT II trial did not
confirm this result (Figure).2 This randomized placebo-
controlled study of 3306 ischemic stroke patients up to 6
hours from ictus demonstrated no significant improvement in
the primary end point of day 90 modified Rankin score
(mRS). Subgroup analyses also failed to replicate the previ-
ous finding of reduced hemorrhagic transformation rate in
patients treated with thrombolytic.
Although the result was disappointing, the trial itself was
rigorous and it optimized statistical analyses to describe
functional outcomes across the treatment groups. A clear
message from the SAINT trials is that even large-scale
meticulously planned trials are subject to the play of chance,
and that initial positive results require verification with a
second adequately powered study. These themes have been
echoed in other acute stroke trials throughout the year.
As the European Safe Implementation of Thrombolysis in
Stroke Monitoring Study (SITS-MOST) confirmed safety and
efficacy of intravenous thrombolysis in routine practice, the
stroke community were already advancing knowledge on
novel approaches to reperfusion. The second Desmoteplase in
Ischemic Acute Stroke (DIAS II) study sought to build on the
success of previous studies using the fibrin specific plasmin-
ogen activator desmoteplase.3 The aim was to target therapy
to those most likely to benefit by including only patients with
perfusion-diffusion mismatch of at least 20% total infarct
volume or equivalent CT-perfusion findings. In a cohort of
patients 3 to 9 hours after event, placebo was tested against
intravenous boluses of 90 g/kg and 125 g/kg desmote-
plase. In contrast to previous results, no benefit was found
from desmoteplase; in fact patients treated at highest dose
showed a trend toward excess mortality.
The reasons for this neutral result remain unclear and may
relate to the active agent, to the imaging based protocol, or to
statistical underpowering—at 186 patients this was still a
small trial. It seems unlikely that patients selected for persis-
tence of penumbra 3 to 9 hours after stroke will show a
greater response to thrombolysis than we achieve with rapid
alteplase use. Groups of 60 patients are too small to confirm
treatment effects comparable to those of alteplase when used
under optimal conditions. The excess mortality in the higher
desmoteplase dosage group seems unlikely to relate directly
to desmoteplase as, of the 14 deaths, 9 were considered
nonneurological and 9 occurred 1 week or later after treat-
ment. Were the DIAS trialists simply victims of “significant”
bad luck?
At present the future of desmoteplase is unclear. However,
the evidence base for using penumbral imaging to target acute
therapies continues to grow. The DEFUSE study successfully
used MRI imaging to predict patients likely to benefit from
tPA in the 3- to 6-hour time period,4 a result confirmed in a
recent analysis of pooled data from 5 European centers.5
Intraarterial delivery of thrombolytic has theoretical advan-
tages over intravenous administration, including local deliv-
ery of agent and reduced systemic effects. It is almost a
decade since the PROACT-II study first suggested efficacy of
intraarterial thrombolysis.6 A confirmatory trial was never
completed, although many centers continued to use intraar-
terial lytics for patients ineligible for standard intravenous
therapy. The MELT study (MCA Embolism Local fibrino-
lytic intervention Trial) helps reassure us that the intraarterial
approach represents a viable treatment option.7 This prospec-
tive trial randomized 114 patients, with confirmed occlusion
of the M1 or M2 MCA segment and within 6 hours of event,
to intraarterial urokinase or medical therapy. The trial was
terminated early when intravenous tPA was licensed for
clinical use in Japan. Although no difference was seen on
primary end point (mRS 0 to 2; P0.345; Figure), on
prespecified secondary end point analysis an increase in
patients showing excellent recovery was demonstrated (mRS
0 to 1; P0.045; Figure) with no significant difference in
mortality or hemorrhage.
Primary intracerebral hemorrhage (ICH) is a frustrating
entity, with higher levels of mortality and disability than
ischemic stroke and few proven therapies. Pilot results using
the hemostatic agent recombinant factor VII (rFVII) had
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suggested efficacy, therefore results of the phase III FAST
trial were eagerly awaited.8 In FAST, 821 patients diagnosed
within 3 hours of onset were randomized to rFVII 20 g/kg;
80 g/kg or placebo. Despite a significant dose-dependent
reduction in hematoma growth, no significant difference was
seen in the main end point of the trial of death or severe
disability at 90 days. These data seem counterintuitive: hema-
toma growth is known to be independently associated with poor
outcome. Although this could represent further play of
chance, analysis of trial subpopulations may offer explana-
tion. According to baseline characteristics presented at the
European Stroke Conference in 2007 (http://www.eurostroke.
org/esc_gla_highlights.htm#oral%20presentation, accessed 24/
10/07), more patients in the treatment arms had low conscious
level, had evidence of left ventricular hypertrophy, and had
intraventricular extension of hemorrhage–all powerful pre-
dictors of outcome. It should also be noted that unlike most
acute stroke trials, FAST did not specify an upper age limit.
It seems plausible that rFVII may only impact on outcomes in
a younger, fitter cohort. We await publication of the full
results so that we can consider all likely confounding
influences.
The disappointing result of FAST must be balanced by
promising work in other areas of ICH intervention. The
INTERACT pilot study of blood pressure reduction has
completed initial work demonstrating that rapid reduction of
blood pressure to a target of 140/90 mm Hg is feasible and
well tolerated. In recognition of the grave prognosis associ-
ated with intraventricular hemorrhage the CLEAR trials are
testing local thrombolysis to aid clot resolution. Results to
date are promising with a suggestion of markedly improved
outcomes,9 and a definitive trial is being planned.
Physiological monitoring is an important component of
acute stroke unit care. However, there is little evidence to
guide treatment when parameters become deranged. The
Glucose in Stroke Trial (GIST) was the first multicenter study
of acute glycaemic intervention.10 Patients were randomized
to treatment with a glucose-potassium-insulin infusion (GKI)
to maintain euglycaemia (capillary blood glucose 4 to
7 mmol/L) or placebo. Treatment conferred no benefit either
in terms of 90-day mortality or functional outcome measures
(Figure). This neutral result does not necessarily signal the
end of glycaemic control in acute stroke; at 933 patients the
study population fell well short of the planned 2355 and
although statistically significant, the mean difference in
glucose between GKI and control (0.57 mmol/L) was clini-
cally modest, probably less than can be achieved with insulin
infusion.11 Further trials targeting insulin therapy to patients
with higher baseline sugars are ongoing.
Last year may have been disappointing for acute pharma-
cotherapy but was less so for nondrug intervention. The
Wingspan stenting device was approved by the US Food and
Drug administration in 2005 for use in intracranial stenosis.
An NIH funded registry of 131 stenting outcomes reported a
high degree of technical success (97%) and a low rate of early
complications (4.6%).12 Observational data have also been
reported for the mechanical embolectomy device—the
MERCI retriever. The Multi-MERCI study of 164 patient
outcomes again reported high rates of successful recanalisa-
tion (57.8%) with few periprocedural complications (6.9%).13
Although new tools for use in acute stroke are welcome, these
results should be treated with some caution. Voluntary
registries and single arm studies are likely to overestimate
benefits from treatment. There is now an ethical and scientific
need to build on these observational data with prospective
randomized controlled trials comparing intervention with best
medical therapy.
Malignant MCA infarction is a feared complication of
ischemic stroke, with mortality approaching 80%. Decom-
pressive hemicraniectomy has been practiced for many years
with case-series suggesting potential for good outcomes but
no adequately powered randomized controlled trials. Three
recent European trials have compared hemicraniectomy to
conservative management. Individually the trials provided a
strong suggestion of benefit; however, it took this year’s
pooled analysis to finally prove efficacy. Compared with best
medical treatment, numbers needed to treat to prevent death,
severe disability, or moderate disability are 2, 2, and 4,
respectively.14 It is remarkable that in a complication of
stroke previously considered fatal, intervention can leave a
substantial proportion with slight disability only (Figure).
Having now proven benefit, we must better define optimal
timing and patient characteristics. In these studies the popu-
lation were relatively young (mean age 43 years, maximal age
60 years) and intervention was rapid (less than 48 hours from
stroke).
So perhaps there were fewer successful emergent therapies
in 2007 than we dared to hope. Regardless, we have still
strengthened the evidence base for acute stroke care. Trials
would not be performed if we were already certain of the
outcome, and the major trials of last year, both positive and
neutral, have greatly added to our knowledge of stroke care
and reconfirmed that large scale well conducted clinical trials
are possible in acute stroke. Medicine advances incremen-
tally; we should celebrate the opportunities that await as
much as the successes we have achieved.
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Figure. Functional outcomes in major stroke trials of 2007; for
comparison results of both SAINT trials are presented.
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